Why the study?
Does combination hormone therapy with megestrol acetate and aminoglutethimide-hydrocortisone improve response rates in patients with metastatic breast cancer?
Population
45 patients with metastatic breast cancer, all with measurable sites of disease. Median age 63 years…
Design
Cohort
Follow-up
Median survival time 15 months
Authors
Loading...
Hypothesis-generating for combination endocrine therapy in metastatic breast cancer; randomized trials needed before clinical adoption.
Does combination hormone therapy with megestrol acetate and aminoglutethimide-hydrocortisone improve response rates in patients with metastatic breast cancer?
Combination therapy with megestrol acetate and aminoglutethimide-hydrocortisone yielded a 34% response rate in metastatic breast cancer with manageable toxicity.
Horton et al. (1987) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: